Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Zolmitriptan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 9,622Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PassPort Tech Announces Positive Results of Zolmitriptan for the Treatment of AM
    PassPort Tech Announces Positive Results of Zolmitriptan for the Treatment of AM

    29 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/passport-technologies-inc-announces-positive-interim-phase-i-results-of-zolmitriptan-transdermal-microporation-system-for-the-treatment-of-acute-migraine-302103063.html

    PR NEWSWIRE
    29 Mar 2024
    Share Share
    PassPort Initiated Ph I Trial of Zolmitriptan Transdermal Microporation System
    PassPort Initiated Ph I Trial of Zolmitriptan Transdermal Microporation System

    23 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/passport-technologies-inc-initiated-us-phase-i-clinical-trial-of-zolmitriptan-transdermal-microporation-system-for-the-treatment-of-acute-migraine-302070038.html

    PR NEWSWIRE
    23 Feb 2024
    Share Share
    Migraine patch developer Zosano Pharma suspends program
    Migraine patch developer Zosano Pharma suspends program

    04 May 2022

    // R. Leuty BIZJOURNALS

    https://www.bizjournals.com/sanfrancisco/news/2022/04/29/migraine-patch-job-cuts-fda-zosano-zsan-qtrypta.html

    R. Leuty BIZJOURNALS
    04 May 2022
    Share Share
    FDA Rejects Zosano's Application For Zolmitriptan Microneedle System Again
    FDA Rejects Zosano's Application For Zolmitriptan Microneedle System Again

    22 Feb 2022

    // BENZINGA

    https://www.benzinga.com/general/biotech/22/02/25745155/fda-rejects-zosano-pharmas-application-for-zolmitriptan-microneedle-system-again-shares-plunge

    BENZINGA
    22 Feb 2022
    Share Share
    Padagis Announces The First-to-Market Launch Of An AB Rated Generic Zomig
    Padagis Announces The First-to-Market Launch Of An AB Rated Generic Zomig

    16 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/padagis-announces-the-first-to-market-launch-of-an-ab-rated-generic-version-of-zomig-nasal-spray-301425925.html

    PRNEWSWIRE
    16 Nov 2021
    Share Share
    Padagis Launches AB Rated Generic Version Of Zomig Nasal Spray
    Padagis Launches AB Rated Generic Version Of Zomig Nasal Spray

    16 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/padagis-announces-the-first-to-market-launch-of-an-ab-rated-generic-version-of-zomig-nasal-spray-301425925.html

    PRNEWSWIRE
    16 Nov 2021
    Share Share